Doximity(DOCS) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported Q3 revenue of $185 million, reflecting a 10% year-on-year growth and a 2% beat from the high end of guidance [4][5] - Adjusted EBITDA margin for Q3 was 60%, amounting to $111 million, which was 7% above the high end of guidance [5][12] - Non-GAAP gross margin for Q3 was 91%, down from 93% in the prior year, attributed to increased AI infrastructure investments [12][13] - Free cash flow generated in Q3 was $58.5 million, with cash, cash equivalents, and marketable securities totaling $735 million at the end of the quarter [13][14] Business Line Data and Key Metrics Changes - The company surpassed 3 million registered members, with over 85% of US physicians and two-thirds of NPs and PAs on the platform [5][6] - Unique active users for workflow tools reached a record 720,000 in Q3, marking the largest sequential gain ever [5][6] - Over 300,000 unique prescribers utilized AI products in Q3, with DocsGPT users querying an average of 4 times a week [8][9] Market Data and Key Metrics Changes - The company expects the healthcare and pharma digital advertising market to grow roughly 5% in calendar 2026 [20][22] - The net revenue retention rate was 112% on a trailing twelve-month basis, with top 20 customers showing a higher retention rate of 117% [12][13] Company Strategy and Development Direction - The company aims to strengthen its AI-powered digital platform for doctors, focusing on building trust through its Peer Check program [10][11] - The strategy includes investing in AI infrastructure and development while maintaining adjusted EBITDA margins of 50% or greater [15][18] - The company plans to commercialize its AI tools later in the year, tapping into clients' innovation and upsell budgets [18][44] Management's Comments on Operating Environment and Future Outlook - Management noted short-term industry-wide policy headwinds affecting client budgets, particularly due to recent policy changes [16][17] - Despite Q3 outperformance, the company anticipates a slower start to calendar 2026 but expects to end the year with significantly better growth [17][50] - The company is optimistic about the release of previously unreleased client funds and strong inbound demand for AI engagement [18][50] Other Important Information - The company repurchased $196.8 million worth of shares during Q3 and has a new $500 million open-ended repurchase authorization [14] - The company has over 10,000 U.S. physician experts reviewing clinical answers, enhancing the trustworthiness of its AI tools [10][11] Q&A Session Summary Question: What is the growth rate for the market in calendar year 2026? - Management expects the market to grow roughly 5% in calendar 2026, with MFN agreements impacting client budget deployments [20][22][25] Question: How does the company view AI monetization opportunities? - The company sees a large opportunity in paid search and plans to enter the market with commercial AI products later this year [58] Question: What is the strategy regarding AI infrastructure costs? - The company acknowledges that there will be costs without associated revenue for a few quarters but believes these investments are worthwhile for future growth [44][45] Question: How is the company addressing talent retention in a competitive environment? - The company is focusing on retaining mission-driven talent and offering stock grants to keep key personnel engaged [76][77] Question: What are the expectations for the mid-year upsell season? - Management believes that as client funds are released, there will be opportunities for stronger upsell during the mid-year season [40][41]